These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30580842)

  • 1. Legacy effect in medicine-the expanding horizon!
    Wander GS; Bansal M
    Indian Heart J; 2018; 70(6):769-771. PubMed ID: 30580842
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing cardiovascular disease in diabetes.
    Harvey JN
    Clin Med (Lond); 2004; 4(4):311-4. PubMed ID: 15372888
    [No Abstract]   [Full Text] [Related]  

  • 3. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
    Karpov IuA; Shubina AT
    Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.
    Górriz JL; Cos Claramunt FX; Duque N; Matali A
    Prim Care Diabetes; 2019 Dec; 13(6):485-494. PubMed ID: 31400992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Antidiabetic Agents and Cardiovascular Outcomes.
    Pareek M; Bhatt DL
    Curr Probl Cardiol; 2018 Mar; 43(3):111-126. PubMed ID: 28844525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
    Wikström G; Malmberg K; Rydén L
    Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetic cardiovascular disease lost in translation between endocrinology and cardiology.
    Dagdelen S
    Am J Cardiol; 2008 Oct; 102(8):1115-6. PubMed ID: 18929722
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.
    Holman RR
    Nat Rev Endocrinol; 2018 Feb; 14(2):67-68. PubMed ID: 29302077
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes as a 'cardiovascular disease equivalent': implications for treatment.
    Laakso M
    Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):682-3. PubMed ID: 18797431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular diseases and diabetes mellitus.
    Bandyopadhyay P
    Drug News Perspect; 2006; 19(6):369-75. PubMed ID: 16971974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122
    [No Abstract]   [Full Text] [Related]  

  • 16. Is glucose control important for prevention of cardiovascular disease in diabetes?
    Mannucci E; Dicembrini I; Lauria A; Pozzilli P
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S259-63. PubMed ID: 23882055
    [No Abstract]   [Full Text] [Related]  

  • 17. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Verma S; Bhatt DL; Bain SC; Buse JB; Mann JFE; Marso SP; Nauck MA; Poulter NR; Pratley RE; Zinman B; Michelsen MM; Monk Fries T; Rasmussen S; Leiter LA;
    Circulation; 2018 May; 137(20):2179-2183. PubMed ID: 29760228
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes.
    Doggen K; Nobels F; Scheen AJ; Van Crombrugge P; Van Casteren V; Mathieu C
    J Diabetes Complications; 2013; 27(4):370-5. PubMed ID: 23537603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.